Jade Biosciences presents JADE101 Phase 1 interim data ahead of Phase 2 trial
Jade Biosciences held a conference call on June 1, 2026 to discuss interim Phase 1 data for JADE101, a clinical-stage therapeutic candidate. The company plans to advance to Phase 2 enrollment and potentially Phase 3 registrational studies pending positive results.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day